Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group.

@article{Kuehn1994PrimaryTO,
  title={Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group.},
  author={M W Kuehn and Lothar Wei\ssbach and Axel Hinke},
  journal={Urology},
  year={1994},
  volume={43 2 Suppl},
  pages={61-7}
}
OBJECTIVE To determine if initial chemo-hormone therapy (estramustine phosphate) of metastatic prostate carcinomas can lengthen the period until progression, compared with hormone treatment (goserelin) alone? The time to progression, side effects and prognostic factors were assessed. METHODS The prospective phase III study (II 86 until V 91) involved 243 patients randomized consecutively in two groups. Progress was assessed according to NPCP criteria. RESULTS The following prognostic… CONTINUE READING